ArticleThe Journal of antimicrobial chemotherapy2025
Population pharmacokinetic model of oral minocycline in critically ill adult patients with ventilator-associated pneumonia.
Article in The Journal of antimicrobial chemotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesMultidrug-resistant Acinetobacter baumannii (MDR-A. baumannii) has become an emerging pathogen, causing ventilator-associated pneumonia (VAP), with limited treatment options available. MIN has re-emerged as a potential treatment option for MDR pathogens. However, evidence regarding MIN pharmacokinetic properties in critically ill patients is scarce and primarily limited to IV administration. To address the knowledge gap in regions where IV MIN is unavailable, a prospective, open-label study was conducted to describe the pharmacokinetic properties of orally administered MIN.
methodsThe study included 24 critically ill patients with MDR-A. baumannii VAP. A population PK (popPK) model was developed and the PTA for different MICs was assessed by Monte Carlo simulations. A one-compartment model with first-order absorption and linear elimination best described the data.
resultsThe values of the estimated population parameters were found equal to 183.3 L, 6.55 L/h and 1.66 h⁻¹, for the apparent volume of distribution (V/F), the apparent clearance (CL/F) and the absorption rate constant (ka), respectively (F representing oral bioavailability). PTA analysis showed that for a daily dose of 400 mg, adequate exposure [free AUC/MIC (fAUC/MIC > 25)] was achieved only for MICs ≤ 0.25 mg/L, while for the ratio of fAUC/MIC = 13.75, high PTA values are calculated up to MIC = 0.5 mg/L.
conclusionsThis study provides a popPK model for oral MIN in critically ill adults. The developed popPK model contributes to a better understanding of MIN's PK and can inform dosing strategies and future studies on MIN use in critical care settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.